

# Francesco Bertoni

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/305135/francesco-bertoni-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

362  
papers

14,647  
citations

63  
h-index

111  
g-index

404  
ext. papers

17,014  
ext. citations

5.4  
avg, IF

6.13  
L-index

| #   | Paper  | IF   | Citations |
|-----|--|------|-----------|
| 362 | Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. <i>Nature Immunology</i> , <b>2005</b> , 6, 769-76   | 19.1 | 948       |
| 361 | Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. <i>Nature</i> , <b>2009</b> , 459, 717-21  | 50.4 | 826       |
| 360 | Analysis of the chronic lymphocytic leukemia coding genome: role of NOTCH1 mutational activation. <i>Journal of Experimental Medicine</i> , <b>2011</b> , 208, 1389-401  | 16.6 | 483       |
| 359 | Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia. <i>Blood</i> , <b>2013</b> , 121, 1403-12  | 2.2  | 357       |
| 358 | Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness. <i>Blood</i> , <b>2011</b> , 118, 6904-8  | 2.2  | 298       |
| 357 | The coding genome of splenic marginal zone lymphoma: activation of NOTCH2 and other pathways regulating marginal zone development. <i>Journal of Experimental Medicine</i> , <b>2012</b> , 209, 1537-51                      | 16.6 | 289       |
| 356 | Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 516-32  | 24.3 | 283       |
| 355 | Primary extranodal non-Hodgkin@ lymphomas. Part 1: Gastrointestinal, cutaneous and genitourinary lymphomas. <i>Annals of Oncology</i> , <b>1997</b> , 8, 727-37  | 10.3 | 261       |
| 354 | The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation. <i>Blood</i> , <b>2011</b> , 117, 3391-401  | 2.2  | 249       |
| 353 | Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia. <i>Blood</i> , <b>2012</b> , 119, 2854-62  | 2.2  | 236       |
| 352 | Clinical activity of rituximab in gastric marginal zone non-Hodgkin@ lymphoma resistant to or not eligible for anti-Helicobacter pylori therapy. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 1979-83             | 2.2  | 218       |
| 351 | BET Proteins as Targets for Anticancer Treatment. <i>Cancer Discovery</i> , <b>2018</b> , 8, 24-36   | 24.4 | 215       |
| 350 | The NF-{kappa}B negative regulator TNFAIP3 (A20) is inactivated by somatic mutations and genomic deletions in marginal zone lymphomas. <i>Blood</i> , <b>2009</b> , 113, 4918-21   | 2.2  | 205       |
| 349 | Molecular analysis of the progression from Helicobacter pylori-associated chronic gastritis to mucosa-associated lymphoid-tissue lymphoma of the stomach. <i>New England Journal of Medicine</i> , <b>1998</b> , 338, 804-10 | 59.2 | 196       |
| 348 | The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , <b>2000</b> , 96, 410-419   | 2.2  | 195       |
| 347 | The BET Bromodomain Inhibitor OTX015 Affects Pathogenetic Pathways in Preclinical B-cell Tumor Models and Synergizes with Targeted Drugs. <i>Clinical Cancer Research</i> , <b>2015</b> , 21, 1628-38                        | 12.9 | 188       |
| 346 | Eradication of Borrelia burgdorferi infection in primary marginal zone B-cell lymphoma of the skin. <i>Human Pathology</i> , <b>2000</b> , 31, 263-8   | 3.7  | 183       |

|     |   |      |     |
|-----|---|------|-----|
| 345 | Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK). <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 705-11 | 2.2  | 166 |
| 344 | Stereotyped B-cell receptor is an independent risk factor of chronic lymphocytic leukemia transformation to Richter syndrome. <i>Clinical Cancer Research</i> , <b>2009</b> , 15, 4415-22   | 12.9 | 155 |
| 343 | Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome. <i>Blood</i> , <b>2013</b> , 122, 2673-82   | 2.2  | 154 |
| 342 | Genomic and expression profiling identifies the B-cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2006</b> , 132, 303-16   | 4.5  | 152 |
| 341 | Alteration of BIRC3 and multiple other NF- $\kappa$ B pathway genes in splenic marginal zone lymphoma. <i>Blood</i> , <b>2011</b> , 118, 4930-4   | 2.2  | 151 |
| 340 | The spectrum of MALT lymphoma at different sites: biological and therapeutic relevance. <i>Blood</i> , <b>2016</b> , 127, 2082-92   | 2.2  | 150 |
| 339 | Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , <b>2011</b> , 117, 1595-604   | 2.2  | 145 |
| 338 | Clinical features, treatment and outcome in a series of 93 patients with low-grade gastric MALT lymphoma. <i>Leukemia and Lymphoma</i> , <b>1997</b> , 26, 527-37   | 1.9  | 145 |
| 337 | Chlamydophila psittaci eradication with doxycycline as first-line targeted therapy for ocular adnexae lymphoma: final results of an international phase II trial. <i>Journal of Clinical Oncology</i> , <b>2012</b> , 30, 2988-94                               | 2.2  | 125 |
| 336 | Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma. <i>Blood</i> , <b>2018</b> , 131, 2413-2425   | 2.2  | 122 |
| 335 | The prognosis of clinical monoclonal B cell lymphocytosis differs from prognosis of Rai 0 chronic lymphocytic leukaemia and is recapitulated by biological risk factors. <i>British Journal of Haematology</i> , <b>2009</b> , 146, 64-75                       | 4.5  | 120 |
| 334 | Primary extranodal non-Hodgkin $\times$ lymphomas. Part 2: Head and neck, central nervous system and other less common sites. <i>Annals of Oncology</i> , <b>1999</b> , 10, 1023-33   | 10.3 | 118 |
| 333 | Paris-Trousseau syndrome : clinical, hematological, molecular data of ten new cases. <i>Thrombosis and Haemostasis</i> , <b>2003</b> , 90, 893-7  | 7    | 116 |
| 332 | A SNP microarray and FISH-based procedure to detect allelic imbalances in multiple myeloma: an integrated genomics approach reveals a wide gene dosage effect. <i>Genes Chromosomes and Cancer</i> , <b>2009</b> , 48, 603-14                                   | 5    | 113 |
| 331 | Opposing effects of cancer-type-specific SPOP mutants on BET protein degradation and sensitivity to BET inhibitors. <i>Nature Medicine</i> , <b>2017</b> , 23, 1046-1054  | 50.5 | 102 |
| 330 | Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study. <i>British Journal of Haematology</i> , <b>2009</b> , 144, 492-506   | 4.5  | 100 |
| 329 | Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. <i>Annals of Oncology</i> , <b>2009</b> , 20, 1086-93                                   | 10.3 | 96  |
| 328 | Anaplastic lymphoma kinase in human cancer. <i>Journal of Molecular Endocrinology</i> , <b>2011</b> , 47, R11-23  | 4.5  | 96  |

|     |   |      |    |
|-----|---|------|----|
| 327 | Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. <i>Blood</i> , <b>2009</b> , 114, 4696-702  | 2.2  | 95 |
| 326 | Identification of T cell-restricted genes, and signatures for different T cell responses, using a comprehensive collection of microarray datasets. <i>Journal of Immunology</i> , <b>2005</b> , 175, 7837-47  | 5.3  | 95 |
| 325 | State-of-the-art therapeutics: marginal-zone lymphoma. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 6415-20  | 2.2  | 92 |
| 324 | Concomitant MYC and microRNA cluster miR-17-92 (C13orf25) amplification in human mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 410-2   | 1.9  | 91 |
| 323 | Molecular follow-up in gastric mucosa-associated lymphoid tissue lymphomas: early analysis of the LY03 cooperative trial. <i>Blood</i> , <b>2002</b> , 99, 2541-4   | 2.2  | 91 |
| 322 | Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation. <i>Leukemia</i> , <b>2014</b> , 28, 1334-40  | 10.7 | 90 |
| 321 | The genetics of nodal marginal zone lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1362-73   | 2.2  | 88 |
| 320 | Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. <i>Blood</i> , <b>2014</b> , 123, 1681-90  | 2.2  | 87 |
| 319 | Analysis of the host pharmacogenetic background for prediction of outcome and toxicity in diffuse large B-cell lymphoma treated with R-CHOP21. <i>Leukemia</i> , <b>2009</b> , 23, 1118-26  | 10.7 | 87 |
| 318 | BCL2, BCL6, MYC, MALT 1, and BCL10 rearrangements in nodal diffuse large B-cell lymphomas: a multicenter evaluation of a new set of fluorescent in situ hybridization probes and correlation with clinical outcome. <i>Human Pathology</i> , <b>2009</b> , 40, 645-52 | 3.7  | 87 |
| 317 | Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , <b>2019</b> , 133, 1664-1676   | 2.2  | 87 |
| 316 | A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. <i>Haematologica</i> , <b>2012</b> , 97, 1085-91  | 6.6  | 85 |
| 315 | Role of DNA methylation in the suppression of Apaf-1 protein in human leukaemia. <i>Oncogene</i> , <b>2003</b> , 22, 451-5  | 9.2  | 82 |
| 314 | Identification of a 3-gene model as a powerful diagnostic tool for the recognition of ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , <b>2012</b> , 120, 1274-81  | 2.2  | 80 |
| 313 | Molecular basis of mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 130-40  | 4.5  | 80 |
| 312 | Update on the molecular biology of mantle cell lymphoma. <i>Hematological Oncology</i> , <b>2006</b> , 24, 22-7   | 1.3  | 77 |
| 311 | CHK1 frameshift mutations in genetically unstable colorectal and endometrial cancers <b>1999</b> , 26, 176-180  |      | 76 |
| 310 | Incidence, risk factors and outcome of histological transformation in follicular lymphoma. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 188-96  | 4.5  | 75 |

|     |   |      |    |
|-----|---|------|----|
| 309 | PRDM1/BLIMP1 is commonly inactivated in anaplastic large T-cell lymphoma. <i>Blood</i> , <b>2013</b> , 122, 2683-93   | 2.2  | 75 |
| 308 | Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , <b>2010</b> , 95, 1792-6  | 6.6  | 74 |
| 307 | Novel GC-rich DNA-binding compound produced by a genetically engineered mutant of the mithramycin producer <i>Streptomyces argillaceus</i> exhibits improved transcriptional repressor activity: implications for cancer therapy. <i>Nucleic Acids Research</i> , <b>2006</b> , 34, 1721-34 | 20.1 | 73 |
| 306 | Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. <i>Nature Genetics</i> , <b>2018</b> , 50, 219-228   | 36.3 | 71 |
| 305 | Ocular adnexal MALT lymphoma: an intriguing model for antigen-driven lymphomagenesis and microbial-targeted therapy. <i>Annals of Oncology</i> , <b>2008</b> , 19, 835-46   | 10.3 | 71 |
| 304 | restrains mast cell inflammatory responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2017</b> , 114, E1490-E1499   | 11.5 | 68 |
| 303 | The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus. <i>Oncotarget</i> , <b>2017</b> , 8, 7598-7613  | 3.3  | 66 |
| 302 | Identification of a new subclass of ALK-negative ALCL expressing aberrant levels of ERBB4 transcripts. <i>Blood</i> , <b>2016</b> , 127, 221-32   | 2.2  | 65 |
| 301 | A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. <i>Journal of Experimental Medicine</i> , <b>2006</b> , 203, 1481-92   | 16.6 | 64 |
| 300 | The Krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. <i>Leukemia</i> , <b>2015</b> , 29, 503-7   | 10.7 | 62 |
| 299 | Histologic transformation in marginal zone lymphomas. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2329-35   | 10.3 | 61 |
| 298 | Treatment and prognosis in a series of primary extranodal lymphomas of the ocular adnexa. <i>Annals of Oncology</i> , <b>1998</b> , 9, 779-81   | 10.3 | 60 |
| 297 | Gela histological scoring system for post-treatment biopsies of patients with gastric MALT lymphoma is feasible and reliable in routine practice. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 47-52  | 4.5  | 59 |
| 296 | Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: T-cell infiltration and positioning of malignant B cells. <i>International Journal of Cancer</i> , <b>2010</b> , 127, 2300-12   | 7.5  | 58 |
| 295 | Chronic inflammation and extra-nodal marginal-zone lymphomas of MALT-type. <i>Seminars in Cancer Biology</i> , <b>2014</b> , 24, 33-42  | 12.7 | 57 |
| 294 | MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1087-90  | 1.9  | 57 |
| 293 | 13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2011</b> , 50, 633-43  | 5    | 57 |
| 292 | Molecular characterization of human multiple myeloma cell lines by integrative genomics: insights into the biology of the disease. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 226-38   | 5    | 57 |

|     |   |      |    |
|-----|---|------|----|
| 291 | The cellular origin of mantle cell lymphoma. <i>International Journal of Biochemistry and Cell Biology</i> , <b>2007</b> , 39, 1747-53  | 5.6  | 57 |
| 290 | Genome wide DNA-profiling of HIV-related B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2010</b> , 148, 245-55  | 4.5  | 56 |
| 289 | In vitro activity of cyclin-dependent kinase inhibitor CYC202 (Seliciclib, R-roscovitine) in mantle cell lymphomas. <i>Annals of Oncology</i> , <b>2005</b> , 16, 1169-76                             | 10.3 | 56 |
| 288 | PQR309 Is a Novel Dual PI3K/mTOR Inhibitor with Preclinical Antitumor Activity in Lymphomas as a Single Agent and in Combination Therapy. <i>Clinical Cancer Research</i> , <b>2018</b> , 24, 120-129 | 12.9 | 54 |
| 287 | Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion. <i>British Journal of Haematology</i> , <b>2008</b> , 143, 532-6      | 4.5  | 53 |
| 286 | Reactive perivascular T-cell infiltrate predicts survival in primary central nervous system B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2007</b> , 138, 316-23                       | 4.5  | 53 |
| 285 | Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma. <i>Clinical Cancer Research</i> , <b>2014</b> , 20, 5113-23  | 12.9 | 52 |
| 284 | Genetic lesions in diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , <b>2015</b> , 26, 1069-1080  | 10.3 | 52 |
| 283 | Comparative genome-wide profiling of post-transplant lymphoproliferative disorders and diffuse large B-cell lymphomas. <i>British Journal of Haematology</i> , <b>2006</b> , 134, 27-36               | 4.5  | 52 |
| 282 | mutations and disruptions are poor prognostic biomarkers in mantle cell lymphoma receiving high-dose therapy: a FIL study. <i>Haematologica</i> , <b>2020</b> , 105, 1604-1612                        | 6.6  | 52 |
| 281 | Combined inhibition of Chk1 and Wee1 as a new therapeutic strategy for mantle cell lymphoma. <i>Oncotarget</i> , <b>2015</b> , 6, 3394-408  | 3.3  | 50 |
| 280 | Oncogenic BARD1 isoforms expressed in gynecological cancers. <i>Cancer Research</i> , <b>2007</b> , 67, 11876-85  | 10.1 | 50 |
| 279 | Nodal marginal zone B-cell lymphomas may arise from different subsets of marginal zone B lymphocytes. <i>Blood</i> , <b>2001</b> , 98, 781-6  | 2.2  | 50 |
| 278 | Delving deeper into MALT lymphoma biology. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 22-6   | 15.9 | 50 |
| 277 | Single nucleotide polymorphism-arrays provide new insights in the pathogenesis of post-transplant diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 569-77    | 4.5  | 45 |
| 276 | Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 221-31               | 4.5  | 45 |
| 275 | Gains of MYC locus and outcome in patients with diffuse large B-cell lymphoma treated with R-CHOP. <i>British Journal of Haematology</i> , <b>2011</b> , 155, 274-7                                   | 4.5  | 42 |
| 274 | Interaction of CDCP1 with HER2 enhances HER2-driven tumorigenesis and promotes trastuzumab resistance in breast cancer. <i>Cell Reports</i> , <b>2015</b> , 11, 564-76                                | 10.6 | 41 |

|     |   |      |    |
|-----|---|------|----|
| 273 | DNA methylation profiling identifies two splenic marginal zone lymphoma subgroups with different clinical and genetic features. <i>Blood</i> , <b>2015</b> , 125, 1922-31   | 2.2  | 40 |
| 272 | Marginal zone lymphomas. <i>Hematology/Oncology Clinics of North America</i> , <b>2008</b> , 22, 883-901, viii  | 3.1  | 40 |
| 271 | Cellular and molecular consequences of peroxisome proliferator-activated receptor-gamma activation in ovarian cancer cells. <i>Neoplasia</i> , <b>2006</b> , 8, 851-61  | 6.4  | 40 |
| 270 | Expression of mutated IGHV3-23 genes in chronic lymphocytic leukemia identifies a disease subset with peculiar clinical and biological features. <i>Clinical Cancer Research</i> , <b>2010</b> , 16, 620-8                      | 12.9 | 38 |
| 269 | PRDM1/BLIMP1: a tumor suppressor gene in B and T cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1223-8  | 1.9  | 37 |
| 268 | Low prevalence of Chlamydia psittaci in ocular adnexal lymphomas from Cuban patients. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 104-8  | 1.9  | 37 |
| 267 | Prognostic impact of monocyte count at presentation in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 465-73  | 4.5  | 36 |
| 266 | Genomic profiles of MALT lymphomas: variability across anatomical sites. <i>Haematologica</i> , <b>2011</b> , 96, 1064-666  |      | 36 |
| 265 | Immunoglobulin heavy chain diversity genes rearrangement pattern indicates that MALT-type gastric lymphoma B cells have undergone an antigen selection process. <i>British Journal of Haematology</i> , <b>1997</b> , 97, 830-6 | 4.5  | 36 |
| 264 | Biological and clinical implications of mutations in chronic lymphocytic leukemia. <i>Haematologica</i> , <b>2020</b> , 105, 448-456  | 6.6  | 35 |
| 263 | Two types of BCR interactions are positively selected during leukemia development in the E $\mu$ TCL1 transgenic mouse model of CLL. <i>Blood</i> , <b>2015</b> , 125, 1578-88  | 2.2  | 35 |
| 262 | MYD88 somatic mutations in MALT lymphomas. <i>British Journal of Haematology</i> , <b>2012</b> , 158, 662-4   | 4.5  | 35 |
| 261 | Genome-wide DNA profiling better defines the prognosis of chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2011</b> , 154, 590-9   | 4.5  | 35 |
| 260 | The gastric marginal zone B-cell lymphoma of MALT type. <i>Blood</i> , <b>2000</b> , 96, 410-419  | 2.2  | 35 |
| 259 | MALT lymphomas: pathogenesis can drive treatment. <i>Oncology</i> , <b>2011</b> , 25, 1134-42, 1147   | 1.8  | 35 |
| 258 | Chemical stresses fail to mimic the unfolded protein response resulting from luminal load with unfolded polypeptides. <i>Journal of Biological Chemistry</i> , <b>2018</b> , 293, 5600-5612                                     | 5.4  | 34 |
| 257 | Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas. <i>Hematological Oncology</i> , <b>2010</b> , 28, 62-7  | 1.3  | 34 |
| 256 | Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. <i>Blood</i> , <b>2013</b> , 122, 2233-41   | 2.2  | 33 |

|     |  |      |    |
|-----|--|------|----|
| 255 | Bayesian DNA copy number analysis. <i>BMC Bioinformatics</i> , <b>2009</b> , 10, 10  | 3.6  | 33 |
| 254 | Integrative genomic analysis reveals distinct transcriptional and genetic features associated with chromosome 13 deletion in multiple myeloma. <i>Haematologica</i> , <b>2007</b> , 92, 56-65                          | 6.6  | 33 |
| 253 | The strength of T cell stimulation determines IL-7 responsiveness, secondary expansion, and lineage commitment of primed human CD4+IL-7Rhi T cells. <i>European Journal of Immunology</i> , <b>2008</b> , 38, 30-9     | 6.1  | 33 |
| 252 | A novel patient-derived tumorgraft model with TRAF1-ALK anaplastic large-cell lymphoma translocation. <i>Leukemia</i> , <b>2015</b> , 29, 1390-401   | 10.7 | 32 |
| 251 | Novel insights into the genetics and epigenetics of MALT lymphoma unveiled by next generation sequencing analyses. <i>Haematologica</i> , <b>2019</b> , 104, e558-e561   | 6.6  | 31 |
| 250 | Advances in understanding the pathogenesis of systemic anaplastic large cell lymphomas. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 771-83  | 4.5  | 31 |
| 249 | Intrinsic and extrinsic factors influencing the clinical course of B-cell chronic lymphocytic leukemia: prognostic markers with pathogenetic relevance. <i>Journal of Translational Medicine</i> , <b>2009</b> , 7, 76 | 8.5  | 31 |
| 248 | High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. <i>British Journal of Haematology</i> , <b>2008</b> , 141, 622-30  | 4.5  | 31 |
| 247 | OTX015 (MK-8628), a novel BET inhibitor, exhibits antitumor activity in non-small cell and small cell lung cancer models harboring different oncogenic mutations. <i>Oncotarget</i> , <b>2016</b> , 7, 84675-84687     | 3.3  | 31 |
| 246 | Impairment of both IRE1 expression and XBP1 activation is a hallmark of GCB DLBCL and contributes to tumor growth. <i>Blood</i> , <b>2017</b> , 129, 2420-2428   | 2.2  | 30 |
| 245 | Cardiac involvement in HIV-related non-Hodgkin@ lymphoma: a case report and short review of the literature. <i>Annals of Hematology</i> , <b>1998</b> , 77, 75-8   | 3    | 30 |
| 244 | Patterns of survival of follicular lymphomas at a single institution through three decades. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 1028-34   | 1.9  | 29 |
| 243 | Up-regulation of the hypoxia-inducible factor-1 transcriptional pathway in colorectal carcinomas. <i>Human Pathology</i> , <b>2008</b> , 39, 1483-94   | 3.7  | 29 |
| 242 | Identification of a potential role for POU2AF1 and BTG4 in the deletion of 11q23 in chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2005</b> , 43, 1-10   | 5    | 29 |
| 241 | Preclinical evaluation of the BET bromodomain inhibitor BAY 1238097 for the treatment of lymphoma. <i>British Journal of Haematology</i> , <b>2017</b> , 178, 936-948  | 4.5  | 28 |
| 240 | Simultaneous occurrence of peripheral T-cell lymphoma unspecified and B-cell small lymphocytic lymphoma. Report of 2 cases. <i>Human Pathology</i> , <b>2007</b> , 38, 787-92  | 3.7  | 28 |
| 239 | Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes. <i>Marine Drugs</i> , <b>2020</b> , 18,   | 6    | 28 |
| 238 | Inhibition of Notch pathway arrests PTEN-deficient advanced prostate cancer by triggering p27-driven cellular senescence. <i>Nature Communications</i> , <b>2016</b> , 7, 13719  | 17.4 | 28 |



|     |  |      |    |
|-----|--|------|----|
| 237 | Life expectancy of young adults with follicular lymphoma. <i>Annals of Oncology</i> , <b>2015</b> , 26, 2317-22  | 10.3 | 27 |
| 236 | Risk factors of central nervous system relapse in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2013</b> , 54, 1908-14   | 1.9  | 27 |
| 235 | Chromosome band 6q deletion pattern in malignant lymphomas. <i>Cancer Genetics and Cytogenetics</i> , <b>2006</b> , 165, 106-13  |      | 27 |
| 234 | IDH2 inhibition enhances proteasome inhibitor responsiveness in hematological malignancies. <i>Blood</i> , <b>2019</b> , 133, 156-167  | 2.2  | 27 |
| 233 | Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours. <i>European Journal of Cancer</i> , <b>2008</b> , 44, 1829-34  | 7.5  | 26 |
| 232 | Mantle cell lymphoma. <i>Current Opinion in Hematology</i> , <b>2004</b> , 11, 411-8   | 3.3  | 26 |
| 231 | Recent advances in understanding the biology of marginal zone lymphoma. <i>F1000Research</i> , <b>2018</b> , 7, 4063.6   |      | 25 |
| 230 | Molecular history of Richter syndrome: origin from a cell already present at the time of chronic lymphocytic leukemia diagnosis. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 3006-10   | 7.5  | 24 |
| 229 | Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , <b>2011</b> , 29, 91-9   | 1.3  | 24 |
| 228 | Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , <b>2011</b> , 29, 38-41  | 1.3  | 23 |
| 227 | Immunoglobulin heavy chain genes somatic hypermutations and chromosome 11q22-23 deletion in classic mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research. <i>British Journal of Haematology</i> , <b>2004</b> , 124, 289-98 | 4.5  | 23 |
| 226 | New molecular and therapeutic insights into canine diffuse large B-cell lymphoma elucidates the role of the dog as a model for human disease. <i>Haematologica</i> , <b>2019</b> , 104, e256-e259  | 6.6  | 23 |
| 225 | Serotonin receptor 3A expression in normal and neoplastic B cells. <i>Pathobiology</i> , <b>2010</b> , 77, 129-35  | 3.6  | 22 |
| 224 | Novel HDAC inhibitors exhibit pre-clinical efficacy in lymphoma models and point to the importance of CDKN1A expression levels in mediating their anti-tumor response. <i>Oncotarget</i> , <b>2015</b> , 6, 5059-71                                  | 3.3  | 22 |
| 223 | The ETS Inhibitors YK-4-279 and TK-216 Are Novel Antilymphoma Agents. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5167-5176  | 12.9 | 21 |
| 222 | B-cell receptor, clinical course and prognosis in chronic lymphocytic leukaemia: the growing saga of the IGHV3 subgroup gene usage. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 3-14  | 4.5  | 21 |
| 221 | IgV H mutations in blastoid mantle cell lymphoma characterize a subgroup with a tendency to more favourable clinical outcome. <i>Journal of Pathology</i> , <b>2005</b> , 206, 320-7   | 9.4  | 21 |
| 220 | Lack of CD95/FAS gene somatic mutations in extranodal, nodal and splenic marginal zone B cell lymphomas. <i>Leukemia</i> , <b>2000</b> , 14, 446-8   | 10.7 | 21 |

|     |  |      |    |
|-----|--|------|----|
| 219 | Bromodomain inhibitor OTX015 (MK-8628) combined with targeted agents shows strong in vivo antitumor activity in lymphoma. <i>Oncotarget</i> , <b>2016</b> , 7, 58142-58147   | 3.3  | 21 |
| 218 | Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells. <i>Leukemia</i> , <b>2016</b> , 30, 1805-15  | 10.7 | 20 |
| 217 | Hierarchical clustering analysis of pathologic and molecular data identifies prognostically and biologically distinct groups of colorectal carcinomas. <i>Modern Pathology</i> , <b>2011</b> , 24, 126-37  | 9.8  | 20 |
| 216 | Pyrrolo[2,3-b,4]cyclohepta[1,2-][1,2]oxazoles, a New Class of Antimitotic Agents Active against Multiple Malignant Cell Types. <i>Journal of Medicinal Chemistry</i> , <b>2020</b> , 63, 12023-12042   | 8.3  | 20 |
| 215 | Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas. <i>Annals of Oncology</i> , <b>2016</b> , 27, 1123-1128   | 10.3 | 19 |
| 214 | BCL10 gene mutations rarely occur in lymphoid malignancies. <i>Leukemia</i> , <b>2000</b> , 14, 905-8  | 10.7 | 19 |
| 213 | Inhibition of SYK or BTK augments venetoclax sensitivity in SHP1-negative/BCL-2-positive diffuse large B-cell lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 2416-2428  | 10.7 | 18 |
| 212 | Circulating tumor DNA as a liquid biopsy in plasma cell dyscrasias. <i>Haematologica</i> , <b>2018</b> , 103, e245-e248  | 6.6  | 18 |
| 211 | IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia. <i>Journal of Translational Medicine</i> , <b>2012</b> , 10, 18 | 8.5  | 18 |
| 210 | Del(13q14.3) length matters: an integrated analysis of genomic, fluorescence in situ hybridization and clinical data in 169 chronic lymphocytic leukaemia patients with 13q deletion alone or a normal karyotype. <i>Hematological Oncology</i> , <b>2012</b> , 30, 46-9   | 1.3  | 18 |
| 209 | An open-label phase 2 study of twice-weekly bortezomib and intermittent pegylated liposomal doxorubicin in patients with ovarian cancer failing platinum-containing regimens. <i>International Journal of Gynecological Cancer</i> , <b>2012</b> , 22, 792-800             | 3.5  | 18 |
| 208 | Molecular and transcriptional characterization of the novel 17p11.2-p12 amplicon in multiple myeloma. <i>Genes Chromosomes and Cancer</i> , <b>2007</b> , 46, 1109-18  | 5    | 18 |
| 207 | Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. <i>Oncotarget</i> , <b>2016</b> , 7, 79637-79653  | 3.3  | 18 |
| 206 | Targeting BET bromodomain proteins in cancer: The example of lymphomas. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 215, 107631   | 13.9 | 18 |
| 205 | T-Cell Leukemia/Lymphoma 1 (TCL1): An Oncogene Regulating Multiple Signaling Pathways. <i>Frontiers in Oncology</i> , <b>2018</b> , 8, 317   | 5.3  | 18 |
| 204 | Interleukin-17A promotes the growth of human germinal center derived non-Hodgkin B cell lymphoma. <i>Oncolmmunology</i> , <b>2015</b> , 4, e1030560  | 7.2  | 17 |
| 203 | PCSF: An R-package for network-based interpretation of high-throughput data. <i>PLoS Computational Biology</i> , <b>2017</b> , 13, e1005694  | 5    | 17 |
| 202 | Genome-wide high resolution DNA profiling of hairy cell leukaemia. <i>British Journal of Haematology</i> , <b>2013</b> , 162, 566-9  | 4.5  | 17 |

|     |  |      |    |
|-----|--|------|----|
| 201 | Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , <b>2012</b> , 23, 729-735   | 10.3 | 17 |
| 200 | Autoreactive B cell clones in marginal-zone B cell lymphoma (MALT lymphoma) of the stomach. <i>Leukemia</i> , <b>1998</b> , 12, 247-9  | 10.7 | 17 |
| 199 | Prognostic models for diffuse large B-cell lymphoma. <i>Hematological Oncology</i> , <b>2000</b> , 18, 61-73   | 1.3  | 17 |
| 198 | Characterization of a mantle cell lymphoma cell line resistant to the Chk1 inhibitor PF-00477736. <i>Oncotarget</i> , <b>2015</b> , 6, 37229-40  | 3.3  | 17 |
| 197 | Promoter methylation patterns in Richter syndrome affect stem-cell maintenance and cell cycle regulation and differ from de novo diffuse large B-cell lymphoma. <i>British Journal of Haematology</i> , <b>2013</b> , 163, 194-204 | 4.5  | 16 |
| 196 | Cyclin-dependent kinase inhibitor seliciclib shows in vitro activity in diffuse large B-cell lymphomas. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 158-67  | 1.9  | 16 |
| 195 | Molecular genetics of extranodal marginal zone (MALT-type) B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 35, 57-68   | 1.9  | 16 |
| 194 | The genetic landscape of dural marginal zone lymphomas. <i>Oncotarget</i> , <b>2016</b> , 7, 43052-43061   | 3.3  | 16 |
| 193 | Copanlisib synergizes with conventional and targeted agents including venetoclax in B- and T-cell lymphoma models. <i>Blood Advances</i> , <b>2020</b> , 4, 819-829  | 7.8  | 16 |
| 192 | Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma. <i>PLoS ONE</i> , <b>2019</b> , 14, e0212813  | 3.7  | 15 |
| 191 | Beyond NPM-anaplastic lymphoma kinase driven lymphomagenesis: alternative drivers in anaplastic large cell lymphoma. <i>Current Opinion in Hematology</i> , <b>2013</b> , 20, 374-81   | 3.3  | 15 |
| 190 | Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , <b>2010</b> , 151, 435-9  | 4.5  | 15 |
| 189 | ACKR3 expression on diffuse large B cell lymphoma is required for tumor spreading and tissue infiltration. <i>Oncotarget</i> , <b>2017</b> , 8, 85068-85084  | 3.3  | 15 |
| 188 | IRF4 Mediates the Oncogenic Effects of STAT3 in Anaplastic Large Cell Lymphomas. <i>Cancers</i> , <b>2018</b> , 10,  | 6.6  | 14 |
| 187 | Mutations of CD79A, CD79B and EZH2 genes in immunodeficiency-related non-Hodgkin lymphomas. <i>British Journal of Haematology</i> , <b>2011</b> , 152, 777-80  | 4.5  | 14 |
| 186 | Treatment of gastric marginal zone lymphoma of MALT type. <i>Expert Opinion on Pharmacotherapy</i> , <b>2010</b> , 11, 2141-52   | 4    | 14 |
| 185 | The involvement of microRNA in the pathogenesis of Richter syndrome. <i>Haematologica</i> , <b>2019</b> , 104, 1004-1015   | 4.1  | 14 |
| 184 | BET bromodomain inhibitor birabresib in mantle cell lymphoma: in vivo activity and identification of novel combinations to overcome adaptive resistance. <i>ESMO Open</i> , <b>2018</b> , 3, e000387                               | 6    | 14 |

|     |   |      |    |
|-----|---|------|----|
| 183 | DNA Damage Response Inhibitor Combinations Exert Synergistic Antitumor Activity in Aggressive B-Cell Lymphomas. <i>Molecular Cancer Therapeutics</i> , <b>2019</b> , 18, 1255-1264  | 6.1  | 13 |
| 182 | The novel CD19-targeting antibody-drug conjugate huB4-DGN462 shows improved anti-tumor activity compared to SAR3419 in CD19-positive lymphoma and leukemia models. <i>Haematologica</i> , <b>2019</b> , 104, 1633-1639                | 6.6  | 13 |
| 181 | Large genomic aberrations detected by SNP array are independent prognosticators of a shorter time to first treatment in chronic lymphocytic leukemia patients with normal FISH. <i>Annals of Oncology</i> , <b>2013</b> , 24, 1378-84 | 10.3 | 13 |
| 180 | Antitumor activity of the dual BET and CBP/EP300 inhibitor NEO2734. <i>Blood Advances</i> , <b>2020</b> , 4, 4124-4135  | 5.8  | 13 |
| 179 | Is There a Role for Dual PI3K/mTOR Inhibitors for Patients Affected with Lymphoma?. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,  | 6.3  | 12 |
| 178 | Primary mediastinal large B-cell lymphoma (PMLCL): the need for prospective controlled clinical trials. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 35, 139-46   | 1.9  | 12 |
| 177 | Preclinical antitumor activity of ST7612AA1: a new oral thiol-based histone deacetylase (HDAC) inhibitor. <i>Oncotarget</i> , <b>2015</b> , 6, 5735-48  | 3.3  | 12 |
| 176 | Staining the target: CD37 expression in lymphomas. <i>Blood</i> , <b>2016</b> , 128, 3022-3023  | 2.2  | 12 |
| 175 | The management of nongastric MALT lymphomas. <i>Oncology</i> , <b>2014</b> , 28, 86-93  | 1.8  | 12 |
| 174 | The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents. <i>Haematologica</i> , <b>2019</b> , 104, e307-e309   | 6.6  | 11 |
| 173 | An overview on anti-tubulin agents for the treatment of lymphoma patients. <i>Pharmacology &amp; Therapeutics</i> , <b>2020</b> , 211, 107552   | 13.9 | 11 |
| 172 | Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , <b>2011</b> , 153, 499-503  | 4.5  | 11 |
| 171 | The clinical and biological features of a series of immunophenotypic variant of B-CLL. <i>European Journal of Haematology</i> , <b>2010</b> , 85, 120-9   | 3.8  | 11 |
| 170 | Angiotropic (Intravascular) Large Cell Lymphoma: Case Report and Short Discussion of the Literature. <i>Tumori</i> , <b>1997</b> , 83, 772-775  | 1.7  | 11 |
| 169 | Allelic expression of p73 in human ovarian cancers. <i>Annals of Oncology</i> , <b>1999</b> , 10, 949-53  | 10.3 | 11 |
| 168 | Immunoglobulin light chain kappa deletion rearrangement as a marker of clonality in mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 36, 147-50   | 1.9  | 11 |
| 167 | Whole exome sequencing reveals mutations in FAT1 tumor suppressor gene clinically impacting on peripheral T-cell lymphoma not otherwise specified. <i>Modern Pathology</i> , <b>2020</b> , 33, 179-187                                | 9.8  | 11 |
| 166 | Mutational landscape of canine B-cell lymphoma profiled at single nucleotide resolution by RNA-seq. <i>PLoS ONE</i> , <b>2019</b> , 14, e0215154  | 3.7  | 10 |

|     |  |      |    |
|-----|--|------|----|
| 165 | Inhibition of CHK1 and WEE1 as a new therapeutic approach in diffuse large B cell lymphomas with MYC deregulation. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 129-133  | 4.5  | 10 |
| 164 | A multicentre phase II trial of gemcitabine for the treatment of patients with newly diagnosed, relapsed or chemotherapy resistant mantle cell lymphoma: SAKK 36/03. <i>Hematological Oncology</i> , <b>2009</b> , 27, 154-9 | 1.3  | 10 |
| 163 | Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma. <i>British Journal of Cancer</i> , <b>1997</b> , 76, 36-9            | 8.7  | 10 |
| 162 | Chlamydia or not Chlamydia, that is the question: which is the microorganism associated with MALT lymphomas of the ocular adnexa?. <i>Journal of the National Cancer Institute</i> , <b>2006</b> , 98, 1348-9                | 9.7  | 10 |
| 161 | Management of rare forms of lymphoma. <i>Current Opinion in Oncology</i> , <b>1998</b> , 10, 377-84  | 4.2  | 10 |
| 160 | Clonality assessment in blood of patients with mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 32, 375-9  | 1.9  | 10 |
| 159 | Microsatellite instability in gastric MALT lymphomas and other associated neoplasms. <i>Annals of Oncology</i> , <b>1999</b> , 10, 783-8   | 10.3 | 10 |
| 158 | Genome-wide promoter methylation of hairy cell leukemia. <i>Blood Advances</i> , <b>2019</b> , 3, 384-396  | 7.8  | 10 |
| 157 | Dual functions of SPOP and ERG dictate androgen therapy responses in prostate cancer. <i>Nature Communications</i> , <b>2021</b> , 12, 734   | 17.4 | 10 |
| 156 | Bayesian network data imputation with application to survival tree analysis. <i>Computational Statistics and Data Analysis</i> , <b>2016</b> , 93, 373-387   | 1.6  | 9  |
| 155 | Bromodomain and extra-terminal domain inhibition modulates the expression of pathologically relevant microRNAs in diffuse large B-cell lymphoma. <i>Haematologica</i> , <b>2018</b> , 103, 2049-2058                         | 6.6  | 9  |
| 154 | Absence of NOTCH1 gene mutations in MALT lymphomas. <i>British Journal of Haematology</i> , <b>2012</b> , 157, 382-4   | 4.5  | 9  |
| 153 | The transcription factor ETS1 in lymphomas: friend or foe?. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1975-80   | 1.9  | 9  |
| 152 | Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. <i>Genes Chromosomes and Cancer</i> , <b>2014</b> , 53, 264-73   | 5    | 9  |
| 151 | Multiple myeloma shows no intra-disease clustering of immunoglobulin heavy chain genes. <i>Haematologica</i> , <b>2012</b> , 97, 849-53  | 6.6  | 9  |
| 150 | Integrated DNA copy number and methylation profiling of lymphoid neoplasms using a single array. <i>British Journal of Haematology</i> , <b>2012</b> , 156, 354-7  | 4.5  | 9  |
| 149 | Genomic aberrations affecting the outcome of immunodeficiency-related diffuse large B-cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 71-6   | 1.9  | 9  |
| 148 | Pixantrone: novel mode of action and clinical readouts. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 587-596   | 2.8  | 8  |

|     |  |      |   |
|-----|--|------|---|
| 147 | Single and combined BTK and PI3K inhibition with acalabrutinib and ACP-319 in pre-clinical models of aggressive lymphomas. <i>British Journal of Haematology</i> , <b>2019</b> , 187, 595-601                                    | 4.5  | 8 |
| 146 | Molecular and clinical features of chronic lymphocytic leukemia with stereotyped B-cell receptors in a Ukrainian cohort. <i>Leukemia and Lymphoma</i> , <b>2010</b> , 51, 822-38   | 1.9  | 8 |
| 145 | An integrated Bayesian analysis of LOH and copy number data. <i>BMC Bioinformatics</i> , <b>2010</b> , 11, 321   | 3.6  | 8 |
| 144 | Association of gastric and Waldeyer ring lymphoma: a molecular study. <i>Hematological Oncology</i> , <b>2000</b> , 18, 15-9   | 1.3  | 8 |
| 143 | Clinical significance of bcl-2 (MBR)/JH rearrangement in the peripheral blood of patients with diffuse large B-cell lymphomas. <i>Annals of Oncology</i> , <b>1996</b> , 7, 1023-7   | 10.3 | 8 |
| 142 | The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37-Targeted Radioimmunotherapy in Activated B Cell Like Diffuse Large B Cell Lymphoma Cell Lines. <i>Frontiers in Oncology</i> , <b>2019</b> , 9, 1301 | 5.3  | 8 |
| 141 | The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax. <i>Cancers</i> , <b>2019</b> , 11,  | 6.6  | 7 |
| 140 | A New Network for the Advancement of Marine Biotechnology in Europe and Beyond. <i>Frontiers in Marine Science</i> , <b>2020</b> , 7,  | 4.5  | 7 |
| 139 | Identification of a new family of pyrazolo[3,4-d]pyrimidine derivatives as multitarget Fyn-Blk-Lyn inhibitors active on B- and T-lymphoma cell lines. <i>European Journal of Medicinal Chemistry</i> , <b>2019</b> , 181, 111545 | 6.8  | 7 |
| 138 | Genetic alterations in systemic nodal and extranodal non-cutaneous lymphomas derived from mature T cells and natural killer cells. <i>Cancer Science</i> , <b>2012</b> , 103, 1397-404   | 6.9  | 7 |
| 137 | The changing paradigm of chronic lymphocytic leukemia management. <i>European Journal of Internal Medicine</i> , <b>2013</b> , 24, 401-10  | 3.9  | 7 |
| 136 | Palmar-plantar erythrodysesthesia syndrome due to 5-fluorouracil therapy--an underestimated toxic event?. <i>Acta Oncologica</i> , <b>1997</b> , 36, 653-4   | 3.2  | 7 |
| 135 | Chromosome instability and translocation t(11;18) in primary gastric marginal zone B-cell lymphoma of MALT-type. <i>Hematological Oncology</i> , <b>2007</b> , 25, 184-8   | 1.3  | 7 |
| 134 | Marginal-Zone Lymphomas.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 568-581  | 59.2 | 7 |
| 133 | The Coding Genome of Nodal Marginal Zone Lymphoma Reveals Recurrent Molecular Alterations of PTPRD and Other Jak/Stat Signaling Genes. <i>Blood</i> , <b>2014</b> , 124, 705-705   | 2.2  | 7 |
| 132 | Genetic alterations underlying the pathogenesis of MALT lymphoma. <i>The Hematology Journal</i> , <b>2002</b> , 3, 10-3  |      | 7 |
| 131 | STAT6 activation correlates with cerebrospinal fluid IL-4 and IL-10 and poor prognosis in primary central nervous system lymphoma. <i>Hematological Oncology</i> , <b>2020</b> , 38, 106-110                                     | 1.3  | 7 |
| 130 | Targeting CD205 with the antibody drug conjugate MEN1309/OBT076 is an active new therapeutic strategy in lymphoma models. <i>Haematologica</i> , <b>2020</b> , 105, 2584-2591  | 6.6  | 7 |

|     |  |      |   |
|-----|--|------|---|
| 129 | Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. <i>Leukemia and Lymphoma</i> , <b>2019</b> , 60, 3067-3070 | 1.9  | 6 |
| 128 | HMGA1-pseudogene7 transgenic mice develop B cell lymphomas. <i>Scientific Reports</i> , <b>2020</b> , 10, 7057   | 4.9  | 6 |
| 127 | Another Piece of the MALT Lymphomas Jigsaw. <i>Journal of Clinical Oncology</i> , <b>2005</b> , 23, 4832-4   | 2.2  | 6 |
| 126 | Discovering subgroups of patients from DNA copy number data using NMF on compacted matrices. <i>PLoS ONE</i> , <b>2013</b> , 8, e79720   | 3.7  | 6 |
| 125 | Targeting the DNA damage response for patients with lymphoma: Preclinical and clinical evidences. <i>Cancer Treatment Reviews</i> , <b>2020</b> , 90, 102090   | 14.4 | 6 |
| 124 | Long Non-Coding RNAs as Molecular Signatures for Canine B-Cell Lymphoma Characterization. <i>Non-coding RNA</i> , <b>2019</b> , 5,   | 7.1  | 5 |
| 123 | TCL1A interacts with TP63 and enhances the survival of Raji Burkitt lymphoma cell line. <i>British Journal of Haematology</i> , <b>2018</b> , 183, 509-512   | 4.5  | 5 |
| 122 | Methylation patterns in marginal zone lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , <b>2017</b> , 30, 24-31  | 4.2  | 5 |
| 121 | Gains of CCND3 gene in ocular adnexal MALT lymphomas: an integrated analysis. <i>British Journal of Haematology</i> , <b>2013</b> , 160, 719-22  | 4.5  | 5 |
| 120 | Mantle cell lymphoma: new treatments targeted to the biology. <i>Clinical Lymphoma and Myeloma</i> , <b>2002</b> , 3, 90-6   |      | 5 |
| 119 | A novel phage display based platform for exosome diversity characterization.. <i>Nanoscale</i> , <b>2022</b> ,   | 7.7  | 5 |
| 118 | Establishment of patient-derived tumor xenograft models of mucinous ovarian cancer. <i>American Journal of Cancer Research</i> , <b>2020</b> , 10, 572-580   | 4.4  | 5 |
| 117 | Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2021</b> ,  | 2.2  | 5 |
| 116 | Targeting non-canonical activation of GLI1 by the SOX2-BRD4 transcriptional complex improves the efficacy of HEDGEHOG pathway inhibition in melanoma. <i>Oncogene</i> , <b>2021</b> , 40, 3799-3814              | 9.2  | 5 |
| 115 | Combining Ibrutinib with Chk1 Inhibitors Synergistically Targets Mantle Cell Lymphoma Cell Lines. <i>Targeted Oncology</i> , <b>2018</b> , 13, 235-245   | 5    | 4 |
| 114 | Primary central nervous system lymphoma: Novel precision therapies. <i>Critical Reviews in Oncology/Hematology</i> , <b>2019</b> , 141, 139-145  | 7    | 4 |
| 113 | The novel atypical retinoid ST5589 down-regulates Aurora Kinase A and has anti-tumour activity in lymphoma pre-clinical models. <i>British Journal of Haematology</i> , <b>2015</b> , 171, 378-86                | 4.5  | 4 |
| 112 | Saliva is a reliable and practical source of germline DNA for genome-wide studies in chronic lymphocytic leukemia. <i>Leukemia Research</i> , <b>2011</b> , 35, 1419-22  | 2.7  | 4 |

|     |   |        |
|-----|---|--------|
| 111 | Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. <i>Leukemia Research</i> , <b>2011</b> , 35, 808-13.7  | 4      |
| 110 | Primary mediastinal large B-cell lymphoma: the need for prospective controlled clinical trials. <i>Leukemia and Lymphoma</i> , <b>1999</b> , 35, 537-44   | 1.9 4  |
| 109 | The Importance of Age in Prognosis of Follicular Lymphoma: Clinical Features and Life Expectancy of Patients Younger Than 40 Years. <i>Blood</i> , <b>2011</b> , 118, 1593-1593   | 2.2 4  |
| 108 | First-in-human phase 1-2A study of CB-103, an oral Protein-Protein Interaction Inhibitor targeting pan-NOTCH signalling in advanced solid tumors and blood malignancies.. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, TPS2619-TPS2619 | 2.2 4  |
| 107 | DNA Copy Number Changes in Diffuse Large B Cell Lymphomas. <i>Frontiers in Oncology</i> , <b>2020</b> , 10, 584095  | 5.3 4  |
| 106 | Trabectedin is a novel chemotherapy agent for diffuse large B cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 1022-1025   | 4.5 4  |
| 105 | GPCR Inhibition in Treating Lymphoma. <i>ACS Medicinal Chemistry Letters</i> , <b>2022</b> , 13, 358-364  | 4.3 4  |
| 104 | Integrated analysis of transcriptome, methylome and copy number aberrations data of marginal zone lymphoma and follicular lymphoma in dog. <i>Veterinary and Comparative Oncology</i> , <b>2020</b> , 18, 645-655 <sup>2.5</sup>                  | 3      |
| 103 | Diffuse large B cell lymphoma cell of origin by digital expression profiling in the REAL07 Phase 1-2 study. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 453-456  | 4.5 3  |
| 102 | Population-based outcome analysis of diffuse large B-cell lymphoma in people living with HIV infection and competent individuals. <i>Hematological Oncology</i> , <b>2018</b> , 36, 757-764   | 1.3 3  |
| 101 | Let@ give BACH2 a breath of fresh air. <i>Blood</i> , <b>2017</b> , 130, 696-697  | 2.2 3  |
| 100 | In vitro efficacy of tyrosine kinase inhibitors: SYK and BCR-ABL inhibitors in lymphomas. <i>Hematological Oncology</i> , <b>2011</b> , 29, 164-6   | 1.3 3  |
| 99  | A virtual tissue bank for primary central nervous system lymphomas in immunocompetent individuals. <i>Pathobiology</i> , <b>2007</b> , 74, 264-9  | 3.6 3  |
| 98  | Analysis of BCL-10 gene mutations in ovarian cancer cell lines. <i>Annals of Oncology</i> , <b>1999</b> , 10, 1259  | 10.3 3 |
| 97  | Abstract A219: OTX015, a bromodomain and extraterminal inhibitor, represents a novel agent for ALK positive anaplastic large cell lymphoma. <b>2013</b> ,   | 3      |
| 96  | Abstract 2664: PQR309: Structure-based design, synthesis and biological evaluation of a novel, selective, dual pan-PI3K/mTOR inhibitor <b>2015</b> ,  | 3      |
| 95  | Abstract 3530: Gene expression profile of OTX015, a BET bromodomain inhibitor, in preclinical models of non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC) models <b>2015</b> ,   | 3      |
| 94  | Mutations in Multiple Genes Cause Deregulation of the NFkB Pathway in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2008</b> , 112, 801-801  | 2.2 3  |



|    |   |      |   |
|----|---|------|---|
| 93 | The Brd-Inhibitor OTX015 Is Active in Pre-Clinical Models of Mature B-Cell Lymphoid Tumors. <i>Blood</i> , <b>2012</b> , 120, 1657-1657   | 2.2  | 3 |
| 92 | Identification of Anti-Lymphoma Biomarkers of Response to the Anti-CD37 Antibody Drug Conjugate (ADC) IMG529. <i>Blood</i> , <b>2016</b> , 128, 4187-4187   | 2.2  | 3 |
| 91 | Marginal Zone Lymphomas. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2020</b> , 26, 336-347  | 2.2  | 3 |
| 90 | Study of the antilymphoma activity of pracinostat reveals different sensitivities of DLBCL cells to HDAC inhibitors. <i>Blood Advances</i> , <b>2021</b> , 5, 2467-2480   | 7.8  | 3 |
| 89 | Bromodomain and Extra-Terminal domain inhibitors for lymphoid malignancies. <i>Current Opinion in Hematology</i> , <b>2019</b> , 26, 273-280  | 3.3  | 3 |
| 88 | In vitro demonstration of synergism with pixantrone combined with targeted agents in lymphomas. <i>British Journal of Haematology</i> , <b>2019</b> , 186, 149-152  | 4.5  | 3 |
| 87 | Validation of epigenetic mechanisms regulating gene expression in canine B-cell lymphoma: An in vitro and in vivo approach. <i>PLoS ONE</i> , <b>2018</b> , 13, e0208709  | 3.7  | 3 |
| 86 | Co-occurrence and mutual exclusivity: what cross-cancer mutation patterns can tell us. <i>Trends in Cancer</i> , <b>2021</b> , 7, 823-836   | 12.5 | 3 |
| 85 | Convergent Mutations and Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. <i>Cancer Cell</i> , <b>2015</b> , 27, 744  | 24.3 | 2 |
| 84 | Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. <i>British Journal of Haematology</i> , <b>2010</b> , 150, 229-32                     | 4.5  | 2 |
| 83 | Syk expression patterns differ among B-cell lymphomas. <i>Leukemia Research</i> , <b>2010</b> , 34, e243-5  | 2.7  | 2 |
| 82 | Bendamustine in lymphomas: more to combine?. <i>Leukemia and Lymphoma</i> , <b>2007</b> , 48, 1264-6  | 1.9  | 2 |
| 81 | Marginal Zone B-Cell Lymphomas <b>2006</b> , 381-396  |      | 2 |
| 80 | Extranodal marginal zone B-cell lymphoma genotyping by Alu-polymerase chain reaction. <i>Leukemia and Lymphoma</i> , <b>2000</b> , 38, 605-10   | 1.9  | 2 |
| 79 | Abstract 3853: Humanized NOD/Scid/IL2g <sup>-/-</sup> tumor grafts recapitulate primary anaplastic large cell lymphoma. <b>2013</b> ,   |      | 2 |
| 78 | Abstract 2676: The MEK-inhibitor pimasertib is synergistic with PI3K-delta and BTK inhibitors in lymphoma models <b>2015</b> ,  |      | 2 |
| 77 | Molecular Subtypes of Splenic Marginal Zone Lymphoma (SMZL) Are Associated with Distinct Pathogenic Mechanisms and Outcomes - Interim Analysis of the IELSG46 Study. <i>Blood</i> , <b>2018</b> , 132, 922-922 <sup>2</sup> |      | 2 |
| 76 | Long Term Outcome of Gastric MALT Lymphoma Patients Treated with Anti-Helicobacter (Antibiotic and Proton-Pump Inhibitor) Regimens.. <i>Blood</i> , <b>2007</b> , 110, 2583-2583  | 2.2  | 2 |

|    |   |      |   |
|----|---|------|---|
| 75 | The Brd-Inhibitor OTX015 Shows Pre-Clinical Activity in Anaplastic Large T-Cell Lymphoma (ALCL). <i>Blood</i> , <b>2012</b> , 120, 4872-4872  | 2.2  | 2 |
| 74 | The Pan Class-I PI3K Inhibitor Copanlisib Has Preclinical Activity in Mantle Cell Lymphoma, Marginal Zone Lymphoma and Chronic Lymphocytic Leukemia As Single Agent and in Combination with Other Targeted and Conventional Agents. <i>Blood</i> , <b>2016</b> , 128, 4185-4185 | 2.2  | 2 |
| 73 | Targeting the Epigenome and the Cell Signaling As Novel Therapeutic Approaches for Splenic Marginal Zone Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 4186-4186  | 2.2  | 2 |
| 72 | ASB2 is a direct target of FLI1 that sustains NF- $\kappa$ B pathway activation in germinal center-derived diffuse large B-cell lymphoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2021</b> , 40, 357   | 12.8 | 2 |
| 71 | Targeting pathogenic mechanisms in marginal zone lymphoma: from concepts and beyond. <i>Annals of Lymphoma</i> , <b>2020</b> , 4, 7   | 1.8  | 2 |
| 70 | A Fast Prize-Collecting Steiner Forest Algorithm for Functional Analyses in Biological Networks. <i>Lecture Notes in Computer Science</i> , <b>2017</b> , 263-276   | 0.9  | 2 |
| 69 | Abstract 3526: OTX015 effects in triple-negative breast cancer (TNBC) models are independent of hypoxia conditions and synergistic with other anticancer agents <b>2015</b> ,   |      | 2 |
| 68 | Role of ETS1 in the Transcriptional Network of Diffuse Large B Cell Lymphoma of the Activated B Cell-Like Type. <i>Cancers</i> , <b>2020</b> , 12,  | 6.6  | 2 |
| 67 | cuRnet: an R package for graph traversing on GPU. <i>BMC Bioinformatics</i> , <b>2018</b> , 19, 356   | 3.6  | 2 |
| 66 | MYC network mutations in high-risk chronic lymphocytic leukaemia. <i>Hematological Oncology</i> , <b>2014</b> , 32, 155-7   | 1.3  | 1 |
| 65 | IGHD3-3 fails to behave as unfavourable prognostic marker in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , <b>2010</b> , 149, 299-302  | 4.5  | 1 |
| 64 | Immunoreactivity for cyclin D1 is a reliable marker of gene aberration in plasma cell myeloma but does not specify patients prognosis. <i>Leukemia Research</i> , <b>2008</b> , 32, 1628-32   | 2.7  | 1 |
| 63 | The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23. <i>Leukemia</i> , <b>2002</b> , 16, 1396; author reply 1396-7   | 10.7 | 1 |
| 62 | Targeting Both BET and Crebbp/EP300 Proteins with the Novel Dual Inhibitor NEO2734 Leads to More Preclinical Anti-Tumor Activity in Diffuse Large B Cell Lymphomathan with Single BET or Crebbp/EP300 Inhibitors. <i>Blood</i> , <b>2018</b> , 132, 4174-4174                   | 2.2  | 1 |
| 61 | Secreted Factors Determine Resistance to Idelalisib in Marginal Zone Lymphoma Models of Resistance. <i>Blood</i> , <b>2019</b> , 134, 2569-2569   | 2.2  | 1 |
| 60 | Unmutated IGHV1-69/D3-16/J3 Stereotyped HCDR3 Rearrangements (Subset 6) Are Associated with Indolent Disease Course and Have Outcome Independent of Mutational Status In Early Stage CLL (Rai 0). <i>Blood</i> , <b>2010</b> , 116, 1371-1371                                   | 2.2  | 1 |
| 59 | SNP6 Array Better Defines Chronic Lymphocytic Leukemia (CLL) Prognostic Groups. <i>Blood</i> , <b>2010</b> , 116, 3611-3611   | 2.2  | 1 |
| 58 | The BET-Bromodomain Inhibitor OTX015 Is Active As a Single Agent and in Combination with Other Targeted Drugs in Preclinical Models of Mantle Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 3113-3113  | 2.2  | 1 |

|    |   |     |   |
|----|---|-----|---|
| 57 | BET Bromodomain Inhibitor OTX015 Affects the Expression of Micrnas Involved in the Pathogenesis of Diffuse Large B-Cell Lymphoma. <i>Blood</i> , <b>2014</b> , 124, 4495-4495   | 2.2 | 1 |
| 56 | The Dual PI3K/mTOR Inhibitor PQR309 Has Synergistic Activity with Other Targeted Agents in Diffuse Large B Cell Lymphomas. <i>Blood</i> , <b>2015</b> , 126, 4005-4005  | 2.2 | 1 |
| 55 | ETS1 Phosphorylation at Threonine-38 Is a Marker of B Cell Receptor Activation, Associating with Cell of Origin and Outcome in Diffuse Large B Cell Lymphoma. <i>Blood</i> , <b>2016</b> , 128, 1755-1755   | 2.2 | 1 |
| 54 | TK216, a Novel, Small Molecule Inhibitor of the ETS-Family of Transcription Factors, Displays Anti-Tumor Activity in AML and DLBCL. <i>Blood</i> , <b>2016</b> , 128, 4035-4035   | 2.2 | 1 |
| 53 | Molecular Subgroups of Peripheral T-Cell Lymphoma Evolve By Distinct Genetic Pathways. <i>Blood</i> , <b>2016</b> , 128, 4096-4096  | 2.2 | 1 |
| 52 | KLF4, DAPK1 and SPG20 promoter methylation is not affected by DNMT1 silencing and hypomethylating drugs in lymphoma cells. <i>Oncology Reports</i> , <b>2022</b> , 47,  | 3.5 | 1 |
| 51 | In Vitro Activity of SYK and BCR-ABL Inhibitors in Aggressive Lymphomas.. <i>Blood</i> , <b>2006</b> , 108, 2520-2520   | 2.2 | 1 |
| 50 | Dual Functions of SPOP and ERG Dictate Androgen Therapy Responses in Prostate Cancer  |     | 1 |
| 49 | The Novel PI3K/mTOR Dual Inhibitor PQR309 in Pre-Clinical Lymphoma Models: Demonstration of Anti-Tumor Activity As Single Agent and in Combination and Identification of Gene Expression Signatures Associated with Response. <i>Blood</i> , <b>2014</b> , 124, 1782-1782 | 2.2 | 1 |
| 48 | Fast and Robust Segmentation of Copy Number Profiles Using Multi-Scale Edge Detection   |     | 1 |
| 47 | Molecular History of Richter Syndrome: Origin From a Common Ancestor Cell Already Present at Chronic Lymphocytic Leukemia Diagnosis. <i>Blood</i> , <b>2010</b> , 116, 2425-2425  | 2.2 | 1 |
| 46 | Phenotypical Characterization and Clinical Outcome of Canine Burkitt-Like Lymphoma. <i>Frontiers in Veterinary Science</i> , <b>2021</b> , 8, 647009  | 3.1 | 1 |
| 45 | The bromodomain and extra-terminal domain degrader MZ1 exhibits preclinical anti-tumoral activity in diffuse large B-cell lymphoma of the activated B cell-like type. <i>Exploration of Targeted Anti-tumor Therapy</i> , <b>2021</b> , 2, 586-601                        | 2.5 | 1 |
| 44 | Understanding the mechanism of action of pyrrolo[3,2-]quinoxaline-derivatives as kinase inhibitors. <i>RSC Medicinal Chemistry</i> , <b>2020</b> , 11, 665-675  | 3.5 | 0 |
| 43 | Inhibition of PIM Kinases Targets Synthetic Vulnerabilities and Enhances Antigen Presentation in B-Cell Lymphoma. <i>Blood</i> , <b>2019</b> , 134, 2858-2858   | 2.2 | 0 |
| 42 | Recurrence of the oxazole motif in tubulin colchicine site inhibitors with anti-tumor activity. <i>European Journal of Medicinal Chemistry Reports</i> , <b>2021</b> , 1, 100004  |     | 0 |
| 41 | Assessment of the Antiproliferative Activity of a BET Bromodomain Inhibitor as Single Agent and in Combination in Non-Hodgkin Lymphoma Cell Lines. <i>Methods in Molecular Biology</i> , <b>2016</b> , 1436, 305-12   | 1.4 |   |
| 40 | A Reliable Method to Remove Batch Effects Maintaining Group Differences in Lymphoma Methylation Case Study. <i>Lecture Notes in Computer Science</i> , <b>2019</b> , 24-32  | 0.9 |   |

- 39 Genome-wide DNA profiling identifies clonal heterogeneity in marginal zone lymphomas. *British Journal of Haematology*, **2014**, 164, 896-9 4.5
- 38 Genome-wide DNA profiling of HIV-related B-cell lymphomas. *Methods in Molecular Biology*, **2013**, 973, 213-26 1.4
- 37 B-cell chronic lymphocytic leukemia 786-792
- 36 MALT and other marginal zone lymphomas 104-120
- 35 Pathologic diagnosis: molecular genetics **2013**, 56-81
- 34 MALT lymphoma: extranodal marginal zone B-cell lymphoma of MALT **2013**, 250-262
- 33 Biased immunoglobulin genes rearrangement in mantle cell lymphoma: Hints to identify the normal B-cell counterpart. *Clinical Oncology and Cancer Research*, **2011**, 8, 65-70
- 32 Biological determinants of long-term survival in chronic myelogenous leukemia patients treated with conventional chemotherapy. *Acta Haematologica*, **1997**, 97, 187-8 2.7
- 31 MALT lymphoma and other marginal zone lymphomas **2001**, 126-140
- 30 HMGA1 induces EZH2 overexpression in human B-cell lymphomas. *American Journal of Cancer Research*, **2021**, 11, 2174-2187 4.4
- 29 Inhibition of the B Cell Associated Tyrosine Kinase SYK as a Potential Therapeutic Target in Aggressive Lymphomas.. *Blood*, **2005**, 106, 1469-1469 2.2
- 28 Hierarchy of Human B Cell Regeneration after Rituximab Therapy.. *Blood*, **2006**, 108, 936-936 2.2
- 27 Identification of New Recurrent Lesions and Clinical Subsets by Genome-Wide DNA Profiling in Chronic Lymphocytic Leukemia with 17p Deletion.. *Blood*, **2007**, 110, 4696-4696 2.2
- 26 Genome-Wide DNA Profiling Identifies a Stable Profile Although with Aberrations Targeting the Fibroblast Growth Factor Pathway in Hairy Cell Leukemia.. *Blood*, **2007**, 110, 4698-4698 2.2
- 25 Molecular and Clinical Features of B Cell Chronic Lymphocytic Leukemia (CLL) Carrying Stereotyped B Cell Receptors: An Italian Experience.. *Blood*, **2007**, 110, 3089-3089 2.2
- 24 The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines. *Blood*, **2019**, 134, 2574-2574 2.2
- 23 Identification of a New Subclass of ALK Negative Anaplastic Large Cell Lymphoma Expressing Aberrant Levels of ERBB4 Transcripts. *Blood*, **2014**, 124, 1679-1679 2.2
- 22 Convergent Mutations and New Kinase Fusions Lead to Oncogenic STAT3 Activation in Anaplastic Large Cell Lymphoma. *Blood*, **2014**, 124, 781-781 2.2

|    |   |     |
|----|---|-----|
| 21 | The BET Inhibitor OTX015 (MK-8628) Shows in Vivo Antitumor Activity in Combination with Additional Targeted Agents in Diffuse Large B-Cell Lymphoma (DLBCL). <i>Blood</i> , <b>2015</b> , 126, 5119-5119  | 2.2 |
| 20 | Analysis of the Early Clonal Dynamics in Ibrutinib-Treated Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2016</b> , 128, 4367-4367  | 2.2 |
| 19 | Targeting the PI3K/mTOR Pathway in Lymphoma with PQR309 and PQR620: Single Agent Activity and Synergism with the BCL2 Inhibitor Venetoclax. <i>Blood</i> , <b>2016</b> , 128, 3017-3017   | 2.2 |
| 18 | Identification of DNA Copy Number Variations Associated with the Clinical Outcome in Young Mantle Cell Lymphoma Patients Treated with Cytarabine-Based High Dose Sequential Chemotherapy and Autologous Stem Cell Transplantation in the Prospective from the MCL0208 Phase III Trial from Fondazione Italiana Linfomi (FIL). <i>Blood</i> , <b>2016</b> , 128, 4099-4099 | 2.2 |
| 17 | The Pharmacogenetic Background of the Host Is An Independent Predictor of Outcome and Toxicity in Diffuse Large B Cell Lymphoma Treated with R-CHOP21. <i>Blood</i> , <b>2008</b> , 112, 480-480  | 2.2 |
| 16 | Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , <b>2008</b> , 112, 478-478  | 2.2 |
| 15 | Usage of IGHV4-39 with Stereotypic B Cell Receptor Is An Independent Risk Factor of Chronic Lymphocytic Leukemia Transformation to Richter Syndrome. <i>Blood</i> , <b>2008</b> , 112, 778-778  | 2.2 |
| 14 | Bayesian Joint Estimation of CN and LOH Aberrations. <i>Lecture Notes in Computer Science</i> , <b>2009</b> , 1109-1117   | 2.2 |
| 13 | 13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2010</b> , 116, 3578-3578   | 2.2 |
| 12 | The Molecular Profile of Richter Syndrome Predicts Survival From Transformation: The Role of Clonal Relationship. <i>Blood</i> , <b>2010</b> , 116, 3601-3601   | 2.2 |
| 11 | Analysis of Parameters Predicting Treatment Efficacy and Outcome In Patients with Hairy Cell Leukemia (HCL) Receiving Subcutaneous Cladribine In the ICGHCL2004 Protocol (by the Italian Cooperative Group on HCL). <i>Blood</i> , <b>2010</b> , 116, 1369-1369   | 2.2 |
| 10 | IGH Repertoire Analysis In Multiple Myeloma (MM): Lack of Intra-Disease Homology and Occasional Clustering with Sequences of Other B-Cell Neoplasms Sharing Identical Geographical Origin. <i>Blood</i> , <b>2010</b> , 116, 2951-2951  | 2.2 |
| 9  | BLIMP1 Is Commonly Inactivated In Anaplastic Large T-Cell Lymphomas (ALCL). <i>Blood</i> , <b>2011</b> , 118, 2634-2634   | 2.2 |
| 8  | Central Nervous System (CNS) Relapse In a Population of 143 Patients (Pts) with Mantle Cell Lymphoma (MCL) From Two Centers. <i>Blood</i> , <b>2011</b> , 118, 2660-2660  | 2.2 |
| 7  | Recurrent 11q24.3 Gain Contributes to the Pathogenesis of Diffuse Large B Cell Lymphoma (DLBCL) by Deregulating ETS1 and FLI1. <i>Blood</i> , <b>2011</b> , 118, 1386-1386  | 2.2 |
| 6  | SNP-Arrays Provide New Insights Into the Pathogenesis of Richter Syndrome (RS). <i>Blood</i> , <b>2011</b> , 118, 263-263   | 2.2 |
| 5  | Richter Syndrome (RS): Genome-Wide Promoter Methylation Profile Differs From De Novo Diffuse Large B-Cell Lymphoma (DLBCL) and Affects Genes Involved in Stem-Cell Maintenance and TP53 Pathway. <i>Blood</i> , <b>2011</b> , 118, 1359-1359  | 2.2 |
| 4  | Integrated Mutational and Cytogenetic Analysis Identifies New Prognostic Subgroups in Chronic Lymphocytic Leukemia. <i>Blood</i> , <b>2012</b> , 120, 712-712   | 2.2 |

- 3 Where Do We Stand in the Genomics of Lymphomas? **2013**, 495-541
- 2 MALT Lymphoma (Extranodal Marginal Zone B-Cell Lymphoma) **2013**, 111-126
- 1 Genome-Wide Promoter Methylation Profiling Of Splenic Marginal Zone Lymphoma (SMZL) Identifies Two Subgroups Of Patients With Distinct Genetic and Biologic Features and Different Outcomes. *Blood*, **2013**, 122, 77-77 2.2